20610 Insurance Policy Changes

CPT 20610, in plain terms, covers Clinician slips a needle into a major joint or bursa, such as the shoulder, hip, or knee, to pull off fluid or push in medication, with no ultrasound used to guide it. CPT 20610 is referenced in 5 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 20610 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Official descriptor: CPT 20610 on AAPC

Aetna · Identified Oct 6, 2026Medium impact
Viscosupplementation (CPB 0179, reviewed 2026-09-02)
Aetna Clinical Policy Bulletin 0179 covers viscosupplement (hyaluronate) injections for knee osteoarthritis under commercial medical plans, and considers all other indications experimental, investigational, or unproven. Initial approval requires radiographic evidence of knee osteoarthritis or at least five listed signs and symptoms, knee pain that interferes with functional activities, an inadequate response or adverse effects with non-pharmacologic treatment, an inadequate response, intolerance or contraindication to an analgesic trial for at least 3 months, an inadequate response, intolerance or contraindication to intra-articular steroid injections for at least 3 months, and no total knee replacement scheduled within 6 months of starting treatment. Continuation requires improvement in pain and functional capacity after prior injections and at least 6 months since the last injection in the prior completed series. the policy was last reviewed 09/02/2026, and its next review is listed for 01/28/2027.
Aetna · Identified Aug 19, 2026Medium impact
Viscosupplementation (CPB 0179, reviewed 2026-04-02)
Aetna considers viscosupplement (hyaluronate) injections medically necessary for commercial medical plans to treat knee osteoarthritis when all of the following criteria are met: radiographic evidence of knee osteoarthritis or at least 5 of the listed signs and symptoms, knee pain that interferes with functional activities, an inadequate response or adverse effects from non-pharmacologic treatment, an inadequate response, intolerance or contraindication to at least 3 months of an analgesic trial and to at least 3 months of intra-articular steroid injections, and no total knee replacement scheduled within 6 months of starting treatment. Continuation is considered medically necessary when the member meets the initial criteria, has improved in pain and functional capacity after the previous injections, and at least 6 months have passed since the last injection in the prior completed series. Aetna considers all other indications experimental, investigational or unproven, and precertification may apply to viscosupplementation products for Aetna participating providers and members in applicable plan designs.
Aetna · Identified Aug 16, 2026Medium impact
Knee Arthroscopy / Osteoarthritis of the Knee (CPB 0673, reviewed 2026-02-19)
Aetna's clinical policy bulletin on knee arthroscopy and knee osteoarthritis considers arthroscopic knee surgery, partial meniscectomy, and meniscal repair medically necessary only when the member has significant symptoms, no more than mild osteoarthritis (Kellgren-Lawrence 0, 1, or 2, or modified Outerbridge 0, 1, or 2), radiologic confirmation of the pathology, and failed conservative therapy. Chondroplasty (29877) is integral to other arthroscopic knee procedures and cannot be approved as an isolated request for significant arthritis. Zilretta is considered not medically necessary, and arthroscopic lavage or debridement for knee pain only or severe osteoarthritis, radiofrequency ablation, subchondroplasty and other listed treatments for knee osteoarthritis are considered experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Trigger Point Injections
Trigger point injection of abnormally sensitive areas in muscles, ligaments, joint capsules, tendons and related tissues may be considered medically necessary to relieve spasm and diminish myofascial pain. One reimbursement is made per site, per session, regardless of the number of trigger point injections, and separate billing for the injected drug is not allowed because it is included in the administration of the injection. Reimbursement is limited to ten sessions in a three-month period for tendon sheath, ligament, trigger point or ganglion cyst injections (CPT 20550), two injections per joint within thirty days for small and intermediate joints (CPT 20600 and 20605), and four services per site within thirty days for major joints or bursa (CPT 20610), and no coverage is allowed beyond these treatment limits.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Intra-articular Hyaluronan Injections for Osteoarthritis
Durolane and Euflexxa may be considered medically necessary for painful osteoarthritis of the knee in patients who have insufficient pain relief from conservative nonpharmacologic therapy and simple analgesics. Repeated courses of these two products may be considered medically necessary only when the prior course gave significant pain relief and at least six months have passed since the prior course in the affected knee, and intra-articular hyaluronan injections into joints other than the knee are considered investigational. The other listed hyaluronan products are not covered on any BCBSMS Formulary.

Watch 20610

Get one email when a payer policy names 20610, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

REFERENCE DATA

Payers with rules3

Payers requiring prior auth3

CalViva Health · Effective December 31, 2025
Prior authorization required
CalViva Health CMS-0057-F prior authorization requirements
Community Health Plan of Imperial Valley · Effective December 31, 2025
Prior authorization required
Community Health Plan of Imperial Valley CMS-0057-F prior authorization requirements
Florida Blue · Effective October 1, 2025
Prior authorization required
Florida Blue site of care review process for certain designated hospital outpatient procedures

FREQUENTLY ASKED QUESTIONS

Does CalViva Health require prior authorization for 20610?

CalViva Health lists 20610 on CalViva Health CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does Community Health Plan of Imperial Valley require prior authorization for 20610?

Community Health Plan of Imperial Valley lists 20610 on Community Health Plan of Imperial Valley CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does Florida Blue require prior authorization for 20610?

Florida Blue lists 20610 on Florida Blue site of care review process for certain designated hospital outpatient procedures for commercial plans (list dated October 1, 2025). Verify with the payer before scheduling.

What insurance policy changes affect CPT 20610?

There are 5 tracked policy changes affecting CPT 20610, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 20610?

Payers that have issued tracked updates for CPT 20610 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 20610 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 20610. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for CPT 20610?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

See every payer rule for 20610

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 20610 in one place.

See every payer rule

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Viscosupplementation (CPB 0179, reviewed 2026-09-02)

Viscosupplementation (CPB 0179, reviewed 2026-04-02)

Knee Arthroscopy / Osteoarthritis of the Knee (CPB 0673, reviewed 2026-02-19)

Trigger Point Injections

Intra-articular Hyaluronan Injections for Osteoarthritis

Prior authorization required

Prior authorization required

Prior authorization required

Does CalViva Health require prior authorization for 20610?

Does Community Health Plan of Imperial Valley require prior authorization for 20610?

Does Florida Blue require prior authorization for 20610?

What insurance policy changes affect CPT 20610?

Which payers have updated policy for CPT 20610?

How do I get notified when CPT 20610 policy changes?

Why do payers change policies for CPT 20610?